Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14845549 | 1.00 | HSD17B10 (0.62) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL29935483 | 0.89 | HSD17B10 (0.60) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL28953620 | 0.89 | HSD17B10 (0.60) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL14748405 | 0.87 | HSD17B10 (0.58) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL67044 | 0.87 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL6219872 | 0.87 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL27877016 | 0.87 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL85536 | 0.87 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL67045 | 0.87 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL20492528 | 0.85 | HSD17B10 (0.68) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689377-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | disclosed |
| US-9150554-B2 | Fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| WO-2013039878-A1 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144444-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | HSD17B10 3889/4885SMN1; SMN2 4385/4885NPC1 1409/4885 |
| US-10689377-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | HSD17B10 3889/4885SMN1; SMN2 4385/4885NPC1 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.